Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Europese goedkeuring pembrolizumab voor behandeling van recidief of refractair klassiek HL
mei 2017 | Lymfoom